Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8501949 | 0.83 | CA1 (0.53) | SMN1; SMN2HSD11B1CA1CA2GAA | |
| SCHEMBL2719702 | 0.81 | CA12 (0.54) | SMN1; SMN2CYP19A1TRPV4CA1CA2 | |
| SCHEMBL8900273 | 0.81 | L3MBTL1 (0.47) | SMN1; SMN2CXCR2HSD11B1CA1CA2 | |
| SCHEMBL6938157 | 0.81 | CA12 (0.55) | SMN1; SMN2CA1CA2GAAL3MBTL1 | |
| SCHEMBL3688422 | 0.78 | CA1 (0.44) | CXCR2HSD11B1CA1CA2CXCR1 | |
| SCHEMBL23866658 | 0.78 | HTR1D (0.38) | SMN1; SMN2CXCR2HSD11B1CA1CA2 | |
| SCHEMBL6935409 | 0.78 | CA12 (0.55) | SMN1; SMN2CA1CA2GAAL3MBTL1 | |
| SCHEMBL22444694 | 0.78 | MAPK1 (0.47) | SMN1; SMN2HSD11B1CA1CA2GAA | |
| SCHEMBL6360991 | 0.78 | HSD11B1 (0.46) | SMN1; SMN2CXCR2HSD11B1CA1CA2 | |
| SCHEMBL2001499 | 0.77 | ALDH1A1 (0.63) | CA1CA2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530470-B9 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7585977-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1530470-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | DALLY ROBERT DEAN | 2008-09-04 | — | — | US | disclosed |
| US-7399867-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | GPER1, ESR2, ESR1 | SMN1; SMN2 4010/4885CYP19A1 7/4885CXCR2 3907/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | SMN1; SMN2 4010/4885CYP19A1 7/4885CXCR2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.